Search
ENDRA Life Sciences Inc
NDRAAdd to Watchlist
5.330USD
+0.330+6.60%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
11.35MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-30The current earnings forecast score of ENDRA Life Sciences Inc is 8.00, ranking 165 out of 387 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 30.00 and a low of 30.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.000
Target Price
+400.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
ENDRA Life Sciences Inc
NDRA
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is ENDRA Life Sciences Inc's price target?
Analysts forecast that ENDRA Life Sciences Inc's price target is USD 30.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 30.00.
How have ENDRA Life Sciences IncNDRA's recent earnings per share performed?
The market expectation was USD -1.09, while ENDRA Life Sciences IncNDRA's earnings per share (EPS) for the previous quarter was USD -2.85. EPS for the next quarter is expected at USD -0.84.
What is the analyst rating for ENDRA Life Sciences Inc?
Based on the ratings of ENDRA Life Sciences Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.